|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases expression |
ISO |
enilconazole results in decreased expression of ABCB11 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of ABCC2 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
decreases expression increases expression multiple interactions |
ISO EXP |
enilconazole results in decreased expression of ABCC3 mRNA enilconazole results in increased expression of ABCC3 mRNA [enilconazole co-treated with clothianidin] results in increased expression of ABCC3 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ABCC3 mRNA |
CTD |
PMID:29451352 PMID:33426623 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of ABCD3 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of ACOX1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Adk |
adenosine kinase |
increases expression |
ISO |
enilconazole results in increased expression of ADK mRNA |
CTD |
PMID:32201337 |
|
NCBI chr15:2,863,241...3,246,453
Ensembl chr15:2,863,244...3,246,510
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression multiple interactions increases expression |
ISO EXP |
enilconazole results in decreased expression of ALDH1A1 mRNA [thiacloprid co-treated with enilconazole] results in decreased expression of ALDH1A1 mRNA enilconazole results in increased expression of ALDH1A1 mRNA [enilconazole co-treated with clothianidin] results in increased expression of ALDH1A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:32201337 PMID:33426623 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases expression multiple interactions |
ISO |
enilconazole results in decreased expression of ALDH2 mRNA [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of ALDH2 mRNA; [Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in decreased expression of and results in decreased activity of ALDH2 protein |
CTD |
PMID:32201337 PMID:34830855 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Ano1 |
anoctamin 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of ANO1 mRNA |
CTD |
PMID:29106682 |
|
NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069
|
|
G |
Anxa10 |
annexin A10 |
increases expression |
ISO |
enilconazole results in increased expression of ANXA10 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr16:27,738,712...27,805,648
Ensembl chr16:27,738,712...27,805,648
|
|
G |
Ar |
androgen receptor |
multiple interactions affects binding decreases expression |
ISO |
Dihydrotestosterone inhibits the reaction [enilconazole results in increased activity of AR protein]; enilconazole inhibits the reaction [[6-fluorotestosterone co-treated with Norgestrel] binds to and results in increased activity of AR protein]; enilconazole inhibits the reaction [Dihydrotestosterone results in increased expression of AR mRNA]; enilconazole inhibits the reaction [Metribolone results in increased activity of AR protein] enilconazole binds to AR protein enilconazole results in decreased expression of AR mRNA |
CTD |
PMID:15064155 PMID:18324785 PMID:21310686 PMID:30853599 PMID:33049310 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arg1 |
arginase 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of ARG1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
increases expression |
ISO |
enilconazole results in increased expression of ATP8B1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Cat |
catalase |
increases expression |
ISO |
enilconazole results in increased expression of CAT mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
enilconazole results in increased expression of CCL5 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions decreases expression |
ISO |
[enilconazole co-treated with thiacloprid] results in increased expression of CES2 protein enilconazole results in decreased expression of CES2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects binding decreases expression |
ISO |
enilconazole binds to CFTR protein enilconazole results in decreased expression of CFTR mRNA; enilconazole results in decreased expression of CFTR protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Comt |
catechol-O-methyltransferase |
increases expression |
ISO |
enilconazole results in increased expression of COMT protein |
CTD |
PMID:32201337 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
affects expression |
ISO |
enilconazole affects the expression of CYP11A1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression |
ISO |
enilconazole results in increased expression of CYP17A1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity affects secretion |
ISO |
enilconazole results in decreased activity of CYP19A1 protein enilconazole affects the secretion of CYP19A1 mRNA |
CTD |
PMID:10806373 PMID:15554355 PMID:26141389 PMID:30853599 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity multiple interactions increases expression |
ISO |
enilconazole results in increased activity of CYP1A1 protein enilconazole inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] enilconazole results in increased expression of CYP1A1 mRNA; enilconazole results in increased expression of CYP1A1 protein |
CTD |
PMID:19070657 PMID:21762035 PMID:32194361 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
affects expression multiple interactions |
ISO |
enilconazole affects the expression of CYP1A2 mRNA [clothianidin co-treated with enilconazole] results in increased expression of CYP1A2 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP1A2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP1A2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression multiple interactions |
ISO |
enilconazole results in increased expression of CYP1B1 mRNA [clothianidin co-treated with enilconazole] results in increased expression of CYP1B1 protein |
CTD |
PMID:32201337 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases expression |
ISO |
enilconazole results in increased expression of CYP27A1 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression multiple interactions |
EXP |
enilconazole results in increased expression of CYP2B2 mRNA [enilconazole co-treated with clothianidin] results in increased expression of CYP2B2 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B2 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions affects expression increases expression |
ISO |
[enilconazole co-treated with thiacloprid] results in increased expression of CYP2B6 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP2B9 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP2B6 mRNA enilconazole affects the expression of CYP2B6 mRNA enilconazole results in increased expression of CYP2B10 |
CTD |
PMID:27853109 PMID:32201337 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases expression |
ISO |
enilconazole results in decreased expression of CYP2C19 mRNA; enilconazole results in decreased expression of CYP2C19 protein |
CTD |
PMID:32194361 PMID:32201337 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions decreases expression |
ISO |
[clothianidin co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in decreased expression of CYP2E1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP2E1 mRNA enilconazole results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
affects expression increases expression multiple interactions decreases activity |
ISO |
enilconazole affects the expression of CYP3A4 mRNA enilconazole results in increased expression of CYP3A4 protein [Amiodarone co-treated with Benzoic Acid co-treated with cyproconazole co-treated with flusilazole co-treated with enilconazole co-treated with prochloraz co-treated with propiconazole co-treated with tebuconazole] results in increased expression of CYP3A4 protein; [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 mRNA; [clothianidin co-treated with enilconazole] results in increased expression of CYP3A4 protein; [enilconazole co-treated with methidathion] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid co-treated with clothianidin] results in increased expression of CYP3A4 mRNA; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A4 protein; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A4 mRNA enilconazole results in decreased activity of CYP3A4 protein |
CTD |
PMID:21762035 PMID:25028461 PMID:32201337 PMID:34273450 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions increases expression |
EXP |
[enilconazole co-treated with clothianidin] results in increased expression of CYP3A23-3A1 mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of CYP3A23-3A1 mRNA enilconazole results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
increases expression multiple interactions |
ISO |
enilconazole results in increased expression of CYP3A5 mRNA; enilconazole results in increased expression of CYP3A5 protein [clothianidin co-treated with enilconazole] results in increased expression of CYP3A5 protein; [enilconazole co-treated with thiacloprid] results in increased expression of CYP3A5 protein |
CTD |
PMID:32201337 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases activity |
ISO |
enilconazole results in decreased activity of CYP51A1 protein |
CTD |
PMID:16989930 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410 Ensembl chr 6:30,036,865...30,055,410
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression multiple interactions |
ISO EXP |
enilconazole results in decreased expression of CYP7A1 mRNA enilconazole results in decreased expression of CYP7A1 mRNA; enilconazole results in decreased expression of CYP7A1 protein [enilconazole co-treated with clothianidin] results in decreased expression of CYP7A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:29451352 PMID:32194361 PMID:32201337 PMID:32814239 PMID:33426623 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression |
ISO |
enilconazole results in increased expression of CYP8B1 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dnm1 |
dynamin 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of DNM1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 3:15,604,782...15,648,654
Ensembl chr 3:15,604,784...15,648,538
|
|
G |
Eln |
elastin |
decreases expression multiple interactions |
EXP |
enilconazole results in decreased expression of ELN mRNA [enilconazole co-treated with clothianidin] results in decreased expression of ELN mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of ELN mRNA |
CTD |
PMID:33426623 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
enilconazole binds to and results in increased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
decreases expression multiple interactions |
ISO |
enilconazole results in decreased expression of ESR2 mRNA enilconazole binds to and results in increased activity of ESR2 protein |
CTD |
PMID:30853599 PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fabp6 |
fatty acid binding protein 6 |
decreases expression |
ISO |
enilconazole results in decreased expression of FABP6 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
enilconazole results in increased expression of FAS mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
decreases expression increases expression |
ISO |
enilconazole results in decreased expression of FGF15 mRNA enilconazole results in increased expression of FGF15 mRNA |
CTD |
PMID:29451352 PMID:32814239 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of G6PC1 mRNA |
CTD |
PMID:32194361 PMID:32201337 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression |
ISO |
enilconazole results in increased expression of GPX1 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of GPX2 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression |
ISO |
enilconazole results in increased expression of GSR mRNA |
CTD |
PMID:29451352 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gss |
glutathione synthetase |
decreases expression |
ISO |
enilconazole results in decreased expression of GSS mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:144,047,850...144,078,198
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
[Maneb co-treated with mancozeb co-treated with iprodione co-treated with enilconazole co-treated with Chlorpyrifos co-treated with Diazinon co-treated with Dimethoate] results in increased expression of H2AX protein |
CTD |
PMID:34830855 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239 Ensembl chr 4:44,671,786...44,673,239
|
|
G |
Haao |
3-hydroxyanthranilate 3,4-dioxygenase |
decreases expression |
ISO |
enilconazole results in decreased expression of HAAO mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 6:10,845,235...10,864,863
Ensembl chr 6:10,845,771...10,864,877
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
affects expression |
ISO |
enilconazole affects the expression of HMGCR mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
affects expression |
ISO |
enilconazole affects the expression of HMGCS1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hsd17b13 |
hydroxysteroid (17-beta) dehydrogenase 13 |
decreases expression |
ISO |
enilconazole results in decreased expression of HSD17B13 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
affects expression |
ISO |
enilconazole affects the expression of HSD3B1 mRNA |
CTD |
PMID:30853599 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
enilconazole results in increased expression of IFNG mRNA |
CTD |
PMID:27393971 PMID:32814239 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il17a |
interleukin 17A |
multiple interactions increases expression |
ISO |
enilconazole inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL17A mRNA] enilconazole results in increased expression of IL17A mRNA |
CTD |
PMID:22289359 PMID:32814239 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
ISO |
enilconazole results in increased expression of IL1A mRNA |
CTD |
PMID:32814239 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
enilconazole results in increased expression of IL1B mRNA |
CTD |
PMID:27393971 PMID:32814239 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
enilconazole results in increased expression of IL6 mRNA |
CTD |
PMID:27393971 PMID:32201337 PMID:32814239 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
enilconazole results in increased expression of JUN mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Khk |
ketohexokinase |
decreases expression |
ISO |
enilconazole results in decreased expression of KHK mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 6:25,445,298...25,455,834
Ensembl chr 6:25,445,300...25,455,717
|
|
G |
Klf4 |
KLF transcription factor 4 |
affects expression decreases expression |
ISO |
enilconazole affects the expression of KLF4 mRNA enilconazole results in decreased expression of KLF4 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Ky |
kyphoscoliosis peptidase |
multiple interactions decreases expression |
EXP |
[enilconazole co-treated with clothianidin] results in decreased expression of KY mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of KY mRNA enilconazole results in decreased expression of KY mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 8:103,086,959...103,126,305
Ensembl chr 8:103,086,630...103,126,024
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
ISO |
enilconazole results in increased expression of LCN2 |
CTD |
PMID:27393971 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Lhb |
luteinizing hormone subunit beta |
decreases expression |
EXP |
enilconazole results in decreased expression of LHB protein |
CTD |
PMID:36410587 |
|
NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972 Ensembl chr 1:95,900,984...95,901,972
|
|
G |
Lpl |
lipoprotein lipase |
increases expression |
ISO |
enilconazole results in increased expression of LPL mRNA |
CTD |
PMID:32201337 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Ly6d |
lymphocyte antigen 6 family member D |
decreases expression |
ISO |
enilconazole results in decreased expression of LY6D mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 7:106,643,225...106,644,733
Ensembl chr 7:106,643,232...106,644,733
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases expression |
ISO |
enilconazole results in increased expression of MAPK8 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Megf11 |
multiple EGF-like-domains 11 |
multiple interactions decreases expression |
EXP |
[enilconazole co-treated with clothianidin] results in decreased expression of MEGF11 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of MEGF11 mRNA enilconazole results in decreased expression of MEGF11 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 8:64,892,312...65,218,984
Ensembl chr 8:64,892,387...65,216,061
|
|
G |
Mep1b |
meprin A subunit beta |
affects expression decreases expression |
ISO |
enilconazole affects the expression of MEP1B mRNA enilconazole results in decreased expression of MEP1B mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr18:12,366,126...12,392,840
Ensembl chr18:12,365,289...12,392,840
|
|
G |
Mlxipl |
MLX interacting protein-like |
decreases expression |
ISO |
enilconazole results in decreased expression of MLXIPL mRNA |
CTD |
PMID:32201337 |
|
NCBI chr12:21,541,608...21,577,120
Ensembl chr12:21,543,576...21,577,112
|
|
G |
Mme |
membrane metallo-endopeptidase |
multiple interactions increases expression |
EXP |
[enilconazole co-treated with clothianidin] results in increased expression of MME mRNA; [thiacloprid co-treated with enilconazole] results in increased expression of MME mRNA enilconazole results in increased expression of MME mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 2:147,686,913...147,803,808
Ensembl chr 2:147,722,086...147,803,792
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
decreases expression |
ISO |
enilconazole results in decreased expression of MTTP mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Muc1 |
mucin 1, cell surface associated |
affects expression decreases expression |
ISO |
enilconazole affects the expression of MUC1 mRNA enilconazole results in decreased expression of MUC1 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Muc17 |
mucin 17, cell surface associated |
decreases expression |
ISO |
enilconazole results in decreased expression of MUC17 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr12:19,527,251...19,536,924
Ensembl chr12:19,527,321...19,538,522
|
|
G |
Muc2 |
mucin 2, oligomeric mucus/gel-forming |
affects expression decreases expression |
ISO |
enilconazole affects the expression of MUC2 mRNA enilconazole results in decreased expression of MUC2 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions decreases expression |
ISO |
[clothianidin co-treated with enilconazole] results in decreased expression of NR0B2 mRNA enilconazole results in decreased expression of NR0B2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression increases expression |
ISO |
enilconazole results in decreased expression of NR1H4 mRNA enilconazole results in increased expression of NR1H4 mRNA |
CTD |
PMID:29451352 PMID:32814239 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity |
ISO |
[enilconazole co-treated with methidathion] results in increased activity of NR1I2 protein; enilconazole binds to and results in increased activity of NR1I2 protein; enilconazole inhibits the reaction [Rifampin results in increased activity of NR1I2 protein] enilconazole results in increased activity of NR1I2 protein |
CTD |
PMID:16565514 PMID:17438109 PMID:21115097 PMID:25028461 PMID:29973476 PMID:33049310 More...
|
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions affects response to substance |
ISO |
enilconazole binds to and results in increased activity of NR1I3 protein; enilconazole inhibits the reaction [Androstane-3,17-diol binds to and results in decreased activity of NR1I3 protein] NR1I3 protein affects the susceptibility to enilconazole |
CTD |
PMID:18832183 PMID:27853109 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
decreases expression |
ISO |
enilconazole results in decreased expression of PDK4 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pnpla3 |
patatin-like phospholipase domain containing 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of PNPLA3 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 7:115,293,538...115,314,077
Ensembl chr 7:115,293,538...115,314,077
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
enilconazole binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression |
ISO |
enilconazole results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:32201337 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[enilconazole binds to and results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of and results in decreased secretion of Prostaglandin D2 |
CTD |
PMID:26359731 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rara |
retinoic acid receptor, alpha |
increases activity |
ISO |
enilconazole results in increased activity of RARA protein |
CTD |
PMID:20143881 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rarg |
retinoic acid receptor, gamma |
increases activity |
ISO |
enilconazole results in increased activity of RARG protein |
CTD |
PMID:20143881 |
|
NCBI chr 7:133,367,833...133,390,301
Ensembl chr 7:133,367,833...133,390,177
|
|
G |
Retnlb |
resistin like beta |
affects expression |
ISO |
enilconazole affects the expression of RETNLB mRNA |
CTD |
PMID:29106682 |
|
NCBI chr11:51,983,482...51,985,368
Ensembl chr11:51,983,483...51,985,368
|
|
G |
Rgcc |
regulator of cell cycle |
increases expression |
ISO |
enilconazole results in increased expression of RGCC mRNA |
CTD |
PMID:32201337 |
|
NCBI chr15:54,662,483...54,675,320
Ensembl chr15:54,662,483...54,681,141
|
|
G |
Rora |
RAR-related orphan receptor A |
multiple interactions |
ISO |
enilconazole binds to and results in decreased activity of RORA protein |
CTD |
PMID:22289359 |
|
NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
enilconazole results in decreased expression of SCD mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
increases expression |
ISO |
enilconazole results in increased expression of SLC10A2 mRNA |
CTD |
PMID:32814239 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC12A2 mRNA; enilconazole results in decreased expression of SLC12A2 protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC22A5 mRNA; enilconazole results in decreased expression of SLC22A5 protein |
CTD |
PMID:36150497 |
|
NCBI chr10:38,008,303...38,035,474
Ensembl chr10:38,008,311...38,035,309
|
|
G |
Slc26a3 |
solute carrier family 26 member 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC26A3 mRNA; enilconazole results in decreased expression of SLC26A3 protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 6:48,023,892...48,064,829
Ensembl chr 6:48,023,892...48,064,772
|
|
G |
Slc26a6 |
solute carrier family 26 member 6 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC26A6 mRNA; enilconazole results in decreased expression of SLC26A6 protein |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 8:109,558,968...109,569,778
Ensembl chr 8:109,559,642...109,569,778
|
|
G |
Slc6a1 |
solute carrier family 6 member 1 |
multiple interactions |
EXP |
[enilconazole co-treated with clothianidin] results in decreased expression of SLC6A1 mRNA; [thiacloprid co-treated with enilconazole] results in decreased expression of SLC6A1 mRNA |
CTD |
PMID:33426623 |
|
NCBI chr 4:147,448,961...147,482,295
Ensembl chr 4:147,466,965...147,482,293
|
|
G |
Slc9a3 |
solute carrier family 9 member A3 |
decreases expression |
ISO |
enilconazole results in decreased expression of SLC9A3 mRNA |
CTD |
PMID:29106682 PMID:32814239 |
|
NCBI chr 1:29,124,633...29,167,912
Ensembl chr 1:29,124,674...29,167,417
|
|
G |
Slco4a1 |
solute carrier organic anion transporter family, member 4a1 |
increases expression |
ISO |
enilconazole results in increased expression of SLCO4A1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 3:167,559,177...167,578,307
Ensembl chr 3:167,559,316...167,578,305
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression |
ISO |
enilconazole results in increased expression of SOD1 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases expression |
ISO |
enilconazole results in decreased expression of SOD2 mRNA |
CTD |
PMID:29451352 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Star |
steroidogenic acute regulatory protein |
affects expression decreases expression |
ISO EXP |
enilconazole affects the expression of STAR mRNA enilconazole results in decreased expression of STAR mRNA |
CTD |
PMID:30853599 PMID:36410587 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Sult1b1 |
sulfotransferase family 1B member 1 |
decreases expression |
ISO |
enilconazole results in decreased expression of SULT1B1 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
|
|
G |
Sult1c2a |
sulfotransferase family 1C member 2A |
increases expression |
ISO |
enilconazole results in increased expression of SULT1C2 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734
|
|
G |
Tff3 |
trefoil factor 3 |
decreases expression |
ISO |
enilconazole results in decreased expression of TFF3 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
enilconazole binds to and results in decreased activity of THRA protein |
CTD |
PMID:33049310 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
enilconazole results in increased expression of TNF mRNA |
CTD |
PMID:27393971 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
decreases expression |
ISO |
enilconazole results in decreased expression of UGT2B7 mRNA |
CTD |
PMID:32201337 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|